Previous work from our group has extensively characterised the role of LIMD1 as a tumour suppressor in lung cancer, therefore we investigated the potential of PF-477736 as a therapeutic option against LIMD1-deficient lung cancer cell lines. Here, LIMD1 is linked to neoplasm.